Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting

被引：42

作者：

DiLuigi, Andrea J. ^{[1
]}

Engmann, Lawrence ^{[1
]}

Schmidt, David W. ^{[1
]}

Maier, Donald B. ^{[1
]}

Nulsen, John C. ^{[1
]}

Benadiva, Claudio A. ^{[1
]}

机构：

[1] Univ Connecticut Hlth Ctr, Ctr Adv Reprod Serv, Div Reprod Endocrinol & Infertil, Farmington, CT 06030 USA

来源：

FERTILITY AND STERILITY | 2010年 / 94卷 / 03期

关键词：

GnRH agonist; GnRH antagonist; OHSS; high responder; IN-VITRO FERTILIZATION; HUMAN CHORIONIC-GONADOTROPIN; GNRH ANTAGONIST GANIRELIX; EMBRYO-TRANSFER; FOLLICULAR MATURATION; INVITRO FERTILIZATION; SYNDROME OHSS; OVULATION; IVF; CYCLES;

D O I：

10.1016/j.fertnstert.2009.10.034

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Ninety-four women undergoing IVF with peak E-2 level>4000 pg/mL received leuprolide acetate (LA) trigger (LA trigger group) or had gonadotropins withheld for one or more days (coasting group) followed by hCG trigger, unless cycle cancellation occurred. There were no cases of ovarian hyperstimulation syndrome in either group, and the LA trigger group had significantly more oocytes retrieved (26.9 +/- 9.5 vs. 17.7 +/- 9.3) P<0.001, more normally fertilized oocytes (15.0 +/- 7.8 vs. 10.3 +/- 6.3) P=0.01, and higher clinical and ongoing pregnancy rates than the coasting group (52.5% vs. 27.2%; 49.2% vs. 24.2%, P=0.02 for both comparisons, respectively). (Fertil Steril (R) 2010;94:1111-4. (C)2010 by American Society for Reproductive Medicine.)

引用

页码：1111 / 1114

页数：4

共 52 条

[11] Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review [J].

Delvigne, A ;

Rozenberg, S .

HUMAN REPRODUCTION UPDATE, 2002, 8 (06) :559-577

[12] Review of clinical course and treatment of ovarian hyperstimulation syndrome (OHSS) [J].

Delvigne, A ;

Rozenberg, S .

HUMAN REPRODUCTION UPDATE, 2003, 9 (01) :77-96

[13] A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients [J].

Delvigne, A ;

Rozenberg, S .

HUMAN REPRODUCTION UPDATE, 2002, 8 (03) :291-296

[14] Prevention of severe ovarian hyperstimulation by coasting [J].

Dhont, M ;

Van der Straeten, F ;

De Sutter, P .

FERTILITY AND STERILITY, 1998, 70 (05) :847-850

[15] Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study [J].

Egbase, PE ;

Al Sharhan, M ;

Grudzinskas, JG .

HUMAN REPRODUCTION, 1999, 14 (06) :1421-1425

[16] 'Early coasting" in patients with polycystic ovarian syndrome is consistent with good clinical outcome [J].

Egbase, PE ;

Al Sharhan, M ;

Grudzinskas, JG .

HUMAN REPRODUCTION, 2002, 17 (05) :1212-1216

[17] The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study [J].

Engmann, Lawrence ;

DiLuigi, Andrea ;

Schmidt, David ;

Nulsen, John ;

Maier, Donald ;

Benadiva, Claudio .

FERTILITY AND STERILITY, 2008, 89 (01) :84-91

[18] GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS [J].

Engmann, Lawrence .

REPRODUCTIVE BIOMEDICINE ONLINE, 2006, 13 (05) :639-644

[19] In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols [J].

Farhi, Jacob ;

Ben-Haroush, Avi ;

Lande, Yehezkel ;

Sapir, Onit ;

Pinkas, Haim ;

Fisch, Benjamin .

FERTILITY AND STERILITY, 2009, 91 (02) :377-382

[20] Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization [J].

Fauser, BC ;

de Jong, D ;

Olivennes, F ;

Wramsby, H ;

Tay, C ;

Itskovitz-Eldor, J ;

van Hooren, HG .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (02) :709-715

← 1 2 3 4 5 6 →